Biotechnology Top Companies - Benchmarking, Business Strategy, Deal Strategy, Recent Development, Patent Strategy, Management Outlook

The global biotechnology market size was estimated at USD 1.38 trillion in 2023 and is expected to be worth around USD 4.25 trillion by 2033 and poised to grow at a noteworthy CAGR of 11.8% from 2024 to 2033.

Here are top comapanies of biotechnology market:

1. Lonza Group AG

Headquarter: Singapore

Telephone: +65 6521 4111

Website: www.lonza.com

Company Shanpshot: Lonza Group AG

The company operates in four business segments including Biologics, small molecules, Cell & Gene, and Capsules & Health Ingredients. The biopharmaceutical market has continued to improve positively in 2021 and sales are estimated to expand in the region of 11% across modalities. In addition, rising demand for outsourcing has led to healthy and continuous growth in the Biologics CDMO market, with the least estimated account of 11 to 13% CAGR. The Biologics sector is a leading contract development and manufacturing partner for biopharmaceuticals, serving customers for all clinical and commercial manufacturing needs during the product lifecycle, such as drug product and drug substance manufacturing. The modalities around Biologics such as bio conjugates, mammalian and microbial expression systems, and mRNA. The end-to-end service is supplemented by Drug Product Services facilities.

Small Molecules are one of the major driving factors of biopharmaceutical sales and estimated value of nearly 60% of global market revenue. Additionally, increasing demand owing to enhanced worldwide access to medicine, public health initiatives, demographic trends, pricing reviews, and new drug launches. In the Small Molecules group manages as an integrated development and manufacturing service offers for small molecule drug substances and their mediates. Small Molecules helps its clients through all stages of design, development, and manufacturing, with the capability to extend integrated drug substances to drug product solutions, as well as particle engineering and drug product packaging.

2. AstraZeneca

Headquarter: UK

Telephone: +44 (0)20 3749 5000

Website: www.astrazeneca.com

Company Shanpshot: AstraZeneca

AstraZeneca’s business is structured to achieve growth through innovation and its three strategic objectives. R&D and commercial functions have been organized to improve decision-making and the introduction of new drugs in serious disease areas. To drive the science, the company has disease-area-focused R&D organizations in charge of discovery through late-stage development — one for oncology, biopharmaceuticals (CVRM and R&I), and rare diseases. New vaccines and immune therapies units have been developed for 2022. The Commercial teams, which number around 46,380 people by the end of 2021, were responsible for the company's expansion. In 2021, the company has an active presence in approximately 90 countries and sells its products in more than 130 countries. The R&D efficiency, defined as developing from candidate drug nomination to Phase III completion, increased to 23% in 2021 versus an industry average of 14%. Its scientists published 871 publications, 169 of which were in high-impact' peer-reviewed journals with factors more than 15 (Thomson Reuters 5yr IF score).

3. Pfizer Inc.

Headquarter: United States

Telephone: 1-800-879-3477

Website: www.pfizer.com

Company Shanpshot: Pfizer Inc.

The company regularly reviews its operating segments and the approach used by management to evaluate performance and allocate resources. With the formation of the Consumer Healthcare JV in 2019 and the completion of the spin-off of its Upjohn Business in the fourth quarter of 2020, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines and beginning in the fourth quarter of 2020 operated as a single operating segment engaged in the discovery, development, manufacturing, market, ing, sale, and distribution of biopharmaceutical products worldwide. At the beginning of its fiscal fourth quarter of 2021, The company reorganized its commercial operations and began to manage its commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, its innovative science-based biopharmaceutical business, and PC1, its global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is a science-based medicines business that includes six therapeutic areas – Oncology, Inflammation & Immunology, Rare Diseases, hospitals, Vaccines, and Internal Medicine. The Hospital's therapeutic area commercializes its global portfolio of sterile injectable and anti-infective medicines.

Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute, and sell their products and are supported by global platform functions that are responsible for the research, development, manufacturing, and supply of their products and global corporate enabling functions. Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. its chief operating decision-maker uses the venues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma is the only reportable segment. The company has revised prior-period information (Revenues and Earnings, as defined by the management) to conform to the current management structure.

4. Gilead Sciences, Inc.

Headquarter: United States

Telephone: +1 650-574-3000

Website: www.gilead.com

Company Shanpshot: Gilead Sciences, Inc.

The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

5. F. Hoffmann-La Roche AG

Headquarter: Switzerland

Telephone: + 41 61 6919391

Website: www.roche.com

Company Shanpshot: F. Hoffmann-La Roche AG

Roche's success stems from its management structure, which is science-driven and designed for innovation. It fosters a wide range of scientific methods and encourages innovative solutions. If this is combined with the company's seamless integration of its capabilities in Roche Pharma and Roche Diagnostics, the company is ideally positioned to achieve medical breakthroughs for patients and society. Roche Pharmaceuticals is committed to transforming scientific excellence into effective medicines for patients. It combines cutting-edge research in the United States and Japan, and also over 250 global partners, with global size and reach in clinical development, manufacturing, and commercial operations. Roche Pharma is living proof that scientific innovation results in products that really save and enhance the lives of individuals.

The company focus on cancer, immunology, ophthalmology, infectious diseases, neurology, and rare disease, The company is confident in the tremendous potential of science to translate into treatments that reduce human suffering and keep people alive longer and healthier lives. The company is committed to not only advancing diagnostic solutions that can help healthcare professionals make essential choices for their patient’s health but also to improve the way these critical tools are integrated into health systems around the world at a lower cost while still achieving the best possible outcomes. The company offers integrated solutions for laboratories, clinicians, and healthcare systems in over 100 countries by offering the industry's most comprehensive in vitro diagnostics testing portfolio combined with clinical decision support, consultancy, digital diagnostics, disease management, laboratory automation, and software solutions.

6. Biogen

Headquarter: United States

Telephone: + 1-866-418-2859

Website: https://www.biogen.com/

Company Shanpshot: Biogen

As part of its business strategy, the company establishes business relationships with other companies, universities, and medical research institutions, including licenses, joint ventures, and collaborative arrangements, to assist in the clinical development and/or commercialization of certain of the products and products candidates, as well as to provide support for its research programs. The company also evaluates opportunities to obtain complementary products or rights to products and technologies from other companies, universities, and medical research institutions. a partnership and licencing agreement with Acorda to develop and market fampridine- containing products, such as FAMPYRA, in markets outside of than U.S. The company commercializes three antitumor necrosis factor (TNF) biosimilars in certain European countries under agreements with Samsung Bioepis BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE. It also has the exclusive right to distribute BYOOVIZ, a ranibizumab biosimilar to LUCENTIS that's been approved in the U. S., the European Union, and the United Kingdom in the third quarter of 2021.

7. Bristol-Myers Squibb Company

Headquarter: US

Telephone: + 1-212-546-4000

Website: www.bms.com

Company Shanpshot: Bristol-Myers Squibb Company

BMS is a single-segment company that specializes in the research, development, licensing, manufacture, marketing, distribution, and sale of cutting-edge medicines that help patients overcome life-threatening diseases. A worldwide research and development organization and a supply chain organization are responsible for product discovery, development, manufacture, and supply. the company competes with other global research-based drug companies, as well as smaller research organizations and generic drug producers. The company produced different types of drugs with the help of biotechnology which produced drugs for some of the most serious and difficult-to-treat diseases, including cancer, diabetes, and rheumatoid arthritis. Its products are sold globally, mostly through distributors, wholesalers, specialty pharmacies, and, to a lesser extent, to clinics, retailers, hospitals, and government agencies. Most of the revenue comes from products in the oncology, oncology, cardiovascular, and immunology therapeutic classes.

8. Sanofi S.A.

Headquarter: France

Website: www.sanofi.com

Company Shanpshot: Sanofi S.A.

The Pharmaceuticals segment comprises, for all geographical territories, the commercial operations of the following global franchises: Specialty Care (Dupixent, Neurology & Immunology, Rare Diseases, Oncology, and Rare Blood Disorders) and General Medicines (Diabetes, Cardiovascular & Established Prescription Products), together with research, development, and production activities dedicated to the pharmaceuticals segment. This segment also includes associates whose activities are related to pharmaceuticals. Following the transaction of May 29, 2020, Regeneron is no longer an associate of Sanofi. Consequently, the Pharmaceuticals segment no longer includes Sanofi’s equity-accounted share of Regeneron’s profits for all the periods presented. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities are dedicated to vaccines.

The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for Sanofi's Consumer Healthcare products, together with research, development, and production activities dedicated to those products. Inter-segment transactions are not material.

9. Abbott Laboratories

Headquarter: United States

Telephone: (224) 667-6100

Website: www.abbott.com

Company Shanpshot: Abbott Laboratories

Abbott Laboratories is a worldwide medical device and healthcare corporation based in Abbott Park, Illinois, United States. Abbott's main business is the research, development, manufacturing, and distribution of a wide range of healthcare products. Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices are the four reportable segments for Abbott. The Established Pharmaceutical Products segment encompasses a broad range of branded generic medications made around the world and marketed and sold in emerging markets outside of the United States. Depending on the market covered, Abbott-owned distribution centers and public warehouses sell these items directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers. Certain products are co-marketed or co-promoted with other companies or are licensed from them.

The Diagnostic Products segment contains a diverse range of diagnostic systems and tests that are produced, marketed, and sold around the world. Abbott-owned distribution centers, public warehouses, and third-party distributors typically market and sell these products directly to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic companies.

10. Novartis AG

Headquarter: Switzerland

Telephone: +41-61-324-1111

Website: www.novartis.com

Company Shanpshot: Novartis AG

Innovative Medicines researches, develops, manufactures, distributes, and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. Novartis Oncology consists of the global business franchises Hematology and Solid Tumor and Novartis Pharmaceuticals consist of the global business franchises Immunology, Hepatology and Dermatology; Neuroscience; Ophthalmology; Cardiovascular, Renal and Metabolism; Respiratory and Allergy; and Established Medicines.

Sandoz develops, manufactures, and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Gener is, Sandoz develops, manufactures, and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a broad range of therapeutic areas, as well as finished dosage forms of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures, and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies